浙江震元(000705.SZ):組氨酸、左旋多巴、酪氨酸、絲氨酸等產品已完成中試等待量產
格隆匯3月15日丨浙江震元(000705.SZ)於2023年3月14日星期二下午接受機構調研時表示,生物定向合成上虞產業化基地項目是浙江省生命健康類示範性重大產業項目,目前已開工建設,項目設備招標同步推進中,建設期為2.5年,預計2024年下半年可投產,2025年1月正式生產;設計產能:組氨酸(鹽酸組氨酸)2400噸/年、左旋多巴1000噸/年、酪氨酸1000噸/年。
公司一直關注和追蹤合成生物學技術及應用,較早與中科院系研究所、天津科技大學等高端科研院所開展深度合作,利用“合成生物學技術”研發新產品、新技術,經多年合作,形成氨基酸、功能性脂肪酸、健康糖及抗氧化劑等方向的新產品、新技術,主要用作食品及飼料添加劑、保健食品原料(功能性食品原料)、醫藥原料藥及中間體等,組氨酸、左旋多巴、酪氨酸、絲氨酸等產品已完成中試等待量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.